// App-Quantinova.ai

56 : CPI-0610, Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, As “Add-on” to Ruxolitinib, in Advanced Myelofibrosis Patients with Suboptimal Response: Update of MANIFEST Phase 2 Study

Researchers

Presenter

  • Srdan Verstovsek

Principal Investigators

  • Marina Kremyanskaya

  • Ronald Hoffman

  • Raajit K. Rampal

  • Vikas Gupta

  • Moshe Talpaz

  • Nikki Granacher

  • Brian Leber

  • Jean-Jacques Kiladjian

  • Alessandro Vannucchi

  • Prithviraj Bose

  • Mary Frances McMullin

  • Shireen Sirhan

  • Vincent Ribrag

  • Katarina Luptakova

  • Jessica Christo

  • Jing Wang

  • Jennifer A Mertz

  • Gozde Colak

  • James Shao

  • Suresh Bobba

  • Patrick Trojer

  • Adrian Senderowicz

  • Claire Harrison

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai / The Tisch Cancer Institute, New York, NY

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Leukemia Service, Department of Medicine, Clinical Director, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Rogel Cancer Center, The University of Michigan, Ann Arbor, MI

  • Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium

  • Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Canada

  • Clinical Investigations Center, Saint-Louis hospital, Université de Paris, Paris, France

  • Hematology, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Queen's University Belfast, Belfast, United Kingdom

  • Division of Hematology, Montreal General Hospital, Montreal, QC, Canada

  • Institut Gustave-Roussy, Villejuif, France

  • Constellation Pharmaceuticals, Inc., Cambridge, MA

  • Constellation Pharmaceuticals, CAMBRIDGE, MA

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

Locations

  • United States

  • Canada

  • Belgium

  • France

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Thrombocytopenia

  • Myelofibrosis

  • Anemia

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

  • Nucleoside diphosphate kinase A

  • Calreticulin

  • Red Blood Cells

  • Sustained virological response

Drug/Treatment

  • Ruxolitinib phosphate

  • CPI-0610

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved